Female Pelvic Med Reconstr Surg 2017 Mar/Apr;23(2):151-156
From the *Department of Obstetrics, Gynecology and Reproductive Medicine, University of California San Francisco, Irene Betty Moore Women's Hospital, San Francisco, CA; †University of New Mexico, Albuquerque, NM; ‡University of Alabama at Birmingham, Birmingham, AL; §Brown University, Providence, RI; ∥UT Health Science Center, San Antonio, TX; ¶University of Tennessee Health Science Center, Memphis, TN; **University of Utah, Salt Lake City, UT; ††Oregon Health and Science University, Portland, OR; ‡‡University of Iowa, Iowa City, IA; and §§University of Pennsylvania, Philadelphia, PA; and ∥∥San Francisco Veterans Affairs Medical Center, San Francisco, CA.
Objective: The aim of this study was to identify clinical and demographic characteristics that moderate response to treatment with fesoterodine among women with a diagnosis of urgency-predominant urinary incontinence.
Methods: A multicenter, double-blinded, 12-week randomized controlled trial of pharmacologic therapy for urgency-predominant urinary incontinence in community-dwelling women diagnosed by the 3-item Incontinence Questionnaire (3IQ) was previously performed. Participants (N = 645) were randomized to fesoterodine therapy (4-8 mg daily; n = 322) or placebo (n = 323). Read More